| __timestamp | Ligand Pharmaceuticals Incorporated | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 205018000 |
| Thursday, January 1, 2015 | 5807000 | 392709000 |
| Friday, January 1, 2016 | 5571000 | 299694000 |
| Sunday, January 1, 2017 | 5366000 | 397061000 |
| Monday, January 1, 2018 | 6337000 | 434100000 |
| Tuesday, January 1, 2019 | 11347000 | 782200000 |
| Wednesday, January 1, 2020 | 30419000 | 1119900000 |
| Friday, January 1, 2021 | 62176000 | 2437500000 |
| Saturday, January 1, 2022 | 52827000 | 1560400000 |
| Sunday, January 1, 2023 | 35049000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between Regeneron Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Regeneron consistently outpaced Ligand, with its cost of revenue peaking at approximately $2.44 billion in 2021, a staggering 3,800% increase from 2014. In contrast, Ligand's cost of revenue saw a more modest rise, peaking at around $62 million in 2021, marking a 580% increase from 2014. This stark difference highlights Regeneron's aggressive growth strategy and its ability to scale operations efficiently. Meanwhile, Ligand's steadier growth reflects a more conservative approach. As the pharmaceutical landscape evolves, these trends offer valuable insights into the strategic priorities and operational efficiencies of these industry players.
Cost of Revenue Trends: Johnson & Johnson vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Novartis AG vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Biogen Inc.'s Expenses
Regeneron Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: ADMA Biologics, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and Evotec SE's Expenses